Axonics® Files PMA Supplement with FDA for Fourth Generation Rechargeable NeurostimulatorBusiness Wire • 05/31/22
Axonics: A Strong Medical Device Play With Significant Revenue Growth OpportunitiesSeeking Alpha • 05/30/22
Axonics, Inc. (AXNX) CEO Raymond Cohen on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/08/22
Analysts Estimate Axonics Modulation Technologies (AXNX) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 04/28/22
Axonics® Announces Comprehensive Launch of the Axonics F15™ Recharge-Free Sacral Neuromodulation SystemBusiness Wire • 04/19/22
Axonics® Receives FDA Approval for Recharge-Free Sacral Neuromodulation SystemBusiness Wire • 03/07/22
Axonics, Inc. (AXNX) CEO Raymond Cohen on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/25/22
Axonics Modulation Technologies (AXNX) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/25/22
Earnings Preview: Axonics Modulation Technologies (AXNX) Q4 Earnings Expected to DeclineZacks Investment Research • 02/17/22
Axonics® to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 24Business Wire • 02/03/22
New Study Finds More Than 60% of Adult Women in the U.S. Experience Urinary IncontinenceBusiness Wire • 01/25/22
Axonics® CEO Raymond W. Cohen Receives Lifetime Entrepreneurial Achievement Award by the Southern California Biomedical CouncilBusiness Wire • 11/30/21
Axonics® Ranked the Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 500™Business Wire • 11/17/21